Weight Loss and Improvements in Markers of Metabolic Risk in Overweight and Obese Subjects Completing 56 Weeks of Treatment with Naltrexone SR/Bupropion SR

被引：0
|
作者：
Fujioka, Ken
Billes, Sonja K.
Burns, Colleen
Harris-Collazo, Raul
Kim, Dennis D.
Dunayevich, Eduardo
Greenway, Frank L.
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1928-P
引用
收藏
页码：A520 / A521
页数：2
相关论文
共 50 条
  • [21] Effects of bupropion SR on body weight and depressive symptoms in obese patients treated for 50 weeks
    Goodale, E
    Bradley, P
    Haight, B
    Foster, V
    Richard, N
    Modell, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S258 - S258
  • [22] Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms
    Jain, AK
    Kaplan, RA
    Gadde, KM
    Wadden, TA
    Allison, DB
    Brewer, ER
    Leadbetter, RA
    Richard, N
    Haight, B
    Jamerson, BD
    Buaron, KS
    Metz, A
    OBESITY RESEARCH, 2002, 10 (10): : 1049 - 1056
  • [23] Weight Loss, Inflammatory Markers, and Improvements of Iron Status in Overweight and Obese Children
    Gong, Liya
    Yuan, Feifei
    Teng, Jianhua
    Li, Xue
    Zheng, Sining
    Lin, Liqun
    Deng, Haoyuan
    Ma, Guansheng
    Sun, Changhao
    Li, Ying
    JOURNAL OF PEDIATRICS, 2014, 164 (04): : 795 - U174
  • [24] Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Markers of Cardiometabolic Risk: A Pooled Analysis of Two Phase 3, 56-Week, Double-Blind, Placebo-Controlled Studies
    Aronne, Louis J.
    Hollander, Priscilla
    Wyatt, Holly
    Maier, Holly
    Burns, Colleen
    Kim, Dennis D.
    Dunayevich, Eduardo
    OBESITY, 2010, 18 : S151 - S151
  • [25] A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
    Apovian, Caroline M.
    Aronne, Louis
    Rubino, Domenica
    Still, Christopher
    Wyatt, Holly
    Burns, Colleen
    Kim, Dennis
    Dunayevich, Eduardo
    OBESITY, 2013, 21 (05) : 935 - 943
  • [26] The Naltrexone-Bupropion Combination Reduces the Prevalence of the Metabolic Syndrome and Improves Cardiometabolic Markers in At-Risk Subjects
    Erickson, Janelle
    Greenway, Frank
    Dunayevich, Eduardo
    Tollefson, Gary
    OBESITY, 2008, 16 : S139 - S139
  • [27] Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
    Cho, A-Ra
    Choi, Won-Jun
    Kwon, Yu-Jin
    Lee, Hye Sun
    Ahn, Sung Gwe
    Lee, Ji-Won
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 3325 - 3335
  • [28] Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Weight-Related Quality of Life in a Phase 3, 56-Week, Double-Blind, Placebo-Controlled Study
    Plodkowski, Raymond A.
    Mudalier, Sunder
    Maier, Holly
    Burns, Colleen
    Kim, Dennis D.
    Dunayevich, Eduardo
    OBESITY, 2010, 18 : S151 - S152
  • [29] Influences of Normobaric Hypoxia Training on Physical Fitness and Metabolic Risk Markers in Overweight to Obese Subjects
    Wiesner, Susanne
    Haufe, Sven
    Engeli, Stefan
    Mutschler, Harry
    Haas, Ute
    Luft, Friedrich C.
    Jordan, Jens
    OBESITY, 2010, 18 (01) : 116 - 120
  • [30] A Phase 2B, 24-Week Study Evaluating the Efficacy and Safety of Two Doses of Zonisamide SR/Bupropion SR Combination Therapy in Overweight and Obese Subjects
    Fujioka, Ken
    Rubino, Domenica
    Wyatt, Holly
    Apovian, Caroline
    Greenway, Frank
    Hu, Jay
    Kim, Dennis
    Dunayevich, Eduardo
    Landbloom, Ronald
    DIABETES, 2010, 59 : A481 - A481
12345